9th Nov 2009 18:03
|
For immediate release |
9 November 2009 |
ABCAM PLC
("Abcam" or "the Company")
Director/PDMR Dealings: Share Incentive Plan
Cambridge, UK: Abcam plc (AIM: ABC), the rapidly growing bioscience company that markets antibodies via its own online catalogue, has today been notified of the following transactions under the Abcam plc Share Incentive Plan ("the SIP") to the benefit of the Executive Directors and PDMRs:
|
Name |
Partnership Shares purchased on 5 November 2009 at 935 pence per share |
Matching Shares awarded on 5 November 2009 at 935 pence per share |
Free Shares awarded on 9 November 2009 at 904 pence per share |
|
Jonathan Milner |
160 |
160 |
331 |
|
Jim Warwick |
160 |
160 |
331 |
|
Jeff Iliffe |
160 |
160 |
331 |
|
Mark Bushfield |
13 |
13 |
331 |
|
Jane Cooke |
160 |
160 |
331 |
|
Philippe Cotrel |
60 |
60 |
331 |
The risk of forfeiture attached to the Matching Shares will normally be removed on the third anniversary of the award subject to continued employment and the retention of the Partnership Shares in connection with which they were awarded. The risk of forfeiture attached to the Free Shares will normally be removed on the third anniversary of the award subject to continued employment.
No consideration was paid by the above grantees for the award of the Matching Shares or Free Shares and no consideration is due on the release of the Matching or Free Shares.
For further information please contact:
|
Abcam |
+ 44 (0) 1223 696000 |
|
Jonathan Milner, Chief Executive Officer |
|
|
Jeffrey Iliffe, Chief Financial Officer |
|
|
Numis Securities |
+ 44 (0) 20 7260 1000 |
|
Michael Meade / Nick Westlake - Nominated Adviser |
|
|
James Black - Corporate Broking |
|
|
Buchanan Communications |
+ 44 (0) 20 7466 5000 |
|
Mark Court / Stasa Filiplic |
Notes for editors:
About Abcam plc
Abcam is a producer and distributor of research-grade antibodies headquartered in Cambridge, United Kingdom, with offices in Cambridge, Massachusetts, USA, Tokyo, Japan and Hong Kong. Abcam was admitted to AIM in November 2005 and trades under the ticker symbol ABC. The Company produces and distributes its own and third-party produced antibodies to academic and commercial users throughout the world. Product ordering is available through the Company's website www.abcam.com, where customers are also able to access up-to-date and detailed technical product data sheets. All the antibodies are sold under the Abcam brand name and the Company's vision is to build the world's largest online resource of high-quality and commercially viable antibodies. Abcam now has an online catalogue of over 56,000 products, most of which are antibodies, from over 250 suppliers and employs 243 staff in its four operating companies.
Related Shares:
ABC.L